 - Phase II Group 4 EGFRmut, any T790M, any c-MET, 1L treatment-naïve, 23L antineoplastic: All patients must harbor an EGFR activating mutation and 23L patients must have failed defined as intolerance to treatment or documented disease progression a maximum of 2 prior lines of antineoplastic therapy in the advanced setting 